Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Cyteir Therapeutics's 3-Year RORE % for the quarter that ended in Sep. 2023 was -58.74%.
The industry rank for Cyteir Therapeutics's 3-Year RORE % or its related term are showing as below:
CYTT's 3-Year RORE % is ranked worse than 88.81% of 1394
companies
in the Biotechnology industry
Industry Median: -6.39
vs CYTT: -58.74
Cyteir Therapeutics 3-Year RORE % Historical Data
The historical data trend for Cyteir Therapeutics's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cyteir Therapeutics's 3-Year RORE %
For the Biotechnology subindustry, Cyteir Therapeutics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyteir Therapeutics's 3-Year RORE % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cyteir Therapeutics's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Cyteir Therapeutics's 3-Year RORE % falls into.
Cyteir Therapeutics 3-Year RORE % Calculation
Cyteir Therapeutics's 3-Year RORE % for the quarter that ended in Sep. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2023 and 3-year before.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Cyteir Therapeutics 3-Year RORE % Related Terms
Thank you for viewing the detailed overview of Cyteir Therapeutics's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cyteir Therapeutics (Cyteir Therapeutics) Business Description
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor or MCT inhibitor, initially evaluated in a phase 1/2 study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard-of-care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYTT has been successfully added to your 